Asterias Biotherapeutics Stock Price, News & Analysis (NYSEAMERICAN:AST)

$2.05 -0.05 (-2.38 %)
(As of 02/21/2018 02:18 AM ET)
Previous Close$2.10
Today's Range$2.05 - $2.15
52-Week Range$1.95 - $4.30
Volume177,700 shs
Average Volume256,418 shs
Market Capitalization$111.01 million
P/E Ratio-3.15
Dividend YieldN/A
Beta1.07

About Asterias Biotherapeutics (NYSEAMERICAN:AST)

Asterias Biotherapeutics logoAsterias Biotherapeutics, Inc. is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients' immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient's own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells.

Receive AST News and Ratings via Email

Sign-up to receive the latest news and ratings for AST and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNYSEAMERICAN:AST
CUSIPN/A
Phone+1-510-4563805

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-3.15384615384615
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.65)
Net IncomeN/A
Net Margins-403.38%
Return on Equity-79.80%
Return on Assets-59.45%

Miscellaneous

EmployeesN/A
Outstanding Shares54,150,000

Asterias Biotherapeutics (NYSEAMERICAN:AST) Frequently Asked Questions

What is Asterias Biotherapeutics' stock symbol?

Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST."

How were Asterias Biotherapeutics' earnings last quarter?

Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) announced its earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The biotechnology company had revenue of $1.75 million for the quarter, compared to the consensus estimate of $2.81 million. Asterias Biotherapeutics had a negative net margin of 403.38% and a negative return on equity of 79.80%. View Asterias Biotherapeutics' Earnings History.

When will Asterias Biotherapeutics make its next earnings announcement?

Asterias Biotherapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 26th 2018. View Earnings Estimates for Asterias Biotherapeutics.

Where is Asterias Biotherapeutics' stock going? Where will Asterias Biotherapeutics' stock price be in 2018?

3 brokerages have issued 12 month price objectives for Asterias Biotherapeutics' stock. Their forecasts range from $10.00 to $12.00. On average, they expect Asterias Biotherapeutics' stock price to reach $11.00 in the next twelve months. View Analyst Ratings for Asterias Biotherapeutics.

What are Wall Street analysts saying about Asterias Biotherapeutics stock?

Here are some recent quotes from research analysts about Asterias Biotherapeutics stock:

  • 1. According to Zacks Investment Research, "Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company's technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. " (1/19/2018)
  • 2. HC Wainwright analysts commented, "We remind investors that the company continues to advance the SCiStar Phase 2 trial of AST-OPC1, its lead clinical program, which is enrolling both complete cervical SCI patients (AIS A classification), who have no sensory or motor function at the lowest sacral level on the ASIA impairment scale, and incomplete cervical SCI patients (AIS B classification), who retain some sensory function but no motor function at this level. Among the five cohorts slated to be treated in the trial, the first two have completed enrollment of three and six subjects respectively. Cohort 3, which comprises AIS-A patients treated with 20M cells, should generate six-month efficacy data in 3Q17. Cohort 4, which is composed of AIS- B patients, should also generate six-month efficacy data in late 3Q17. Finally, Cohort 5, which is to enroll five to eight AIS-B subjects for treatment with 20M cells per patient, could complete enrollment in 3Q17 with six-month data available in early 2018." (3/30/2017)
  • 3. FBR & Co analysts commented, "We are transferring coverage of Asterias Biotherapeutics, Inc. (AST) and maintaining our Outperform rating, but we are lowering our price target to $6 (from $10) to reflect a more conservative view. AST is developing therapies in an area of immense promise that can change the practice of medicine. However, the emerging field of regenerative medicine using stem cell therapy is accompanied by increased regulatory and clinical risk. The company’s lead program (AST-OPC1) is a pluripotent stem cell platform, a cell line derived from embryonic stem cells. Pluripotent stem cells are “master cells” and have the potential to differentiate into any cell type, as well as reproduce indefinitely. AST’s pluripotent stem cells, AST-OPC1, are differentiated into oligodendrocyte progenitor cells, which are glial cells in the central nervous system. AST-OPC1 is being developed for spinal cord injuries (SCIs) and is in a Phase I/IIa trial testing higher doses for safety and efficacy. There is no cure or effective therapy approved for SCI that can rehabilitate patients." (3/7/2017)

Are investors shorting Asterias Biotherapeutics?

Asterias Biotherapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 2,915,560 shares, an increase of 11.9% from the January 12th total of 2,605,402 shares. Based on an average daily trading volume, of 244,712 shares, the days-to-cover ratio is currently 11.9 days. Approximately 9.2% of the shares of the company are short sold.

Who are some of Asterias Biotherapeutics' key competitors?

Who are Asterias Biotherapeutics' key executives?

Asterias Biotherapeutics' management team includes the folowing people:

  • Don M. Bailey, Chairman of the Board (Age 70)
  • Michael H. Mulroy, President, Chief Executive Officer, Director (Age 51)
  • Ryan Daniel Chavez, Chief Financial Officer, General Counsel (Age 40)
  • Casey C. Case Ph.D., Senior Vice President - Research and Nonclinical Development (Age 59)
  • Edward D. Wirth III, Chief Medical Officer (Age 50)
  • Stephen L. Cartt, Director (Age 53)
  • Alfred D. Kingsley, Director (Age 74)
  • Aditya P. Mohanty, Director (Age 50)
  • Robert W. Peabody CPA, Director (Age 60)
  • Howard I. Scher, Director (Age 64)

Who owns Asterias Biotherapeutics stock?

Asterias Biotherapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.13%), Deutsche Bank AG (0.12%) and Millennium Management LLC (0.11%). Company insiders that own Asterias Biotherapeutics stock include Alfred D Kingsley, Edward Wirth, Katharine E Spink, Michael H Mulroy, Natale S Ricciardi, Richard T Lebuhn and Stephen Lahue Cartt. View Institutional Ownership Trends for Asterias Biotherapeutics.

Who bought Asterias Biotherapeutics stock? Who is buying Asterias Biotherapeutics stock?

Asterias Biotherapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Virtu Financial LLC and Deutsche Bank AG. Company insiders that have bought Asterias Biotherapeutics stock in the last two years include Alfred D Kingsley, Michael H Mulroy, Natale S Ricciardi, Richard T Lebuhn and Stephen Lahue Cartt. View Insider Buying and Selling for Asterias Biotherapeutics.

How do I buy Asterias Biotherapeutics stock?

Shares of Asterias Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Asterias Biotherapeutics' stock price today?

One share of Asterias Biotherapeutics stock can currently be purchased for approximately $2.05.

How big of a company is Asterias Biotherapeutics?

Asterias Biotherapeutics has a market capitalization of $111.01 million.

How can I contact Asterias Biotherapeutics?

Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The biotechnology company can be reached via phone at +1-510-4563805.


MarketBeat Community Rating for Asterias Biotherapeutics (AST)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  71
MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Asterias Biotherapeutics (NYSEAMERICAN:AST) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.00$11.00$11.33$11.33
Price Target Upside: 340.00% upside340.00% upside344.44% upside271.58% upside

Asterias Biotherapeutics (NYSEAMERICAN:AST) Consensus Price Target History

Price Target History for Asterias Biotherapeutics (NYSEAMERICAN:AST)

Asterias Biotherapeutics (NYSEAMERICAN:AST) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
1/8/2018HC WainwrightSet Price TargetBuy$11.00View Rating Details
4/4/2017LaidlawInitiated CoverageBuy -> Buy$12.00View Rating Details
3/7/2017FBR & CoBoost Price TargetOutperform$6.00 -> $10.00View Rating Details
5/23/2016Chardan CapitalInitiated CoverageBuy$5.50View Rating Details
5/17/2016Rodman & RenshawReiterated RatingBuy$10.00View Rating Details
(Data available from 2/21/2016 forward)

Earnings

Asterias Biotherapeutics (NYSEAMERICAN:AST) Earnings History and Estimates Chart

Earnings by Quarter for Asterias Biotherapeutics (NYSEAMERICAN:AST)

Asterias Biotherapeutics (NYSEAMERICAN AST) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/26/2018($0.15)N/AView Earnings Details
11/14/2017Q3 2017($0.15)($0.15)$1.43 million$1.69 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.18)($0.18)$1.25 million$0.32 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.18)($0.17)$1.63 million$2.01 millionViewN/AView Earnings Details
3/28/2017Q4($0.17)($0.18)$2.81 million$1.75 millionViewN/AView Earnings Details
11/14/2016Q316($0.17)($0.24)$1.50 million$2.10 millionViewN/AView Earnings Details
8/15/2016Q216($0.19)($0.12)$1.14 million$1.53 millionViewListenView Earnings Details
5/16/2016Q116($0.14)($0.27)$1.60 millionViewListenView Earnings Details
3/29/2016Q415($0.13)($0.13)$1.07 million$0.61 millionViewListenView Earnings Details
11/9/2015Q315($0.11)($0.06)$1.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.11)($0.10)$0.10 million$0.77 millionViewListenView Earnings Details
5/7/2015($0.13)($0.14)$0.10 million$0.78 millionViewN/AView Earnings Details
3/10/2015($0.13)($0.11)$1.07 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.05)$0.09 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.09)$0.02 millionViewN/AView Earnings Details
5/12/2014Q1 2014($0.07)$0.06 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Asterias Biotherapeutics (NYSEAMERICAN:AST) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Asterias Biotherapeutics (NYSEAMERICAN:AST)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Asterias Biotherapeutics (NYSEAMERICAN AST) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Asterias Biotherapeutics (NYSEAMERICAN:AST)
Institutional Ownership by Quarter for Asterias Biotherapeutics (NYSEAMERICAN:AST)

Asterias Biotherapeutics (NYSEAMERICAN AST) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/25/2018Michael H MulroyInsiderBuy2,134$2.34$4,993.56View SEC Filing  
12/26/2017Michael H MulroyInsiderBuy2,247$2.22$4,988.34View SEC Filing  
11/27/2017Michael H MulroyInsiderBuy2,076$2.41$5,003.16View SEC Filing  
10/25/2017Michael H MulroyInsiderBuy1,939$2.55$4,944.45View SEC Filing  
9/25/2017Michael H. MulroyInsiderBuy1,537$3.25$4,995.25View SEC Filing  
1/9/2017Edward WirthInsiderSell3,415$4.60$15,709.003,415View SEC Filing  
1/9/2017Katharine E SpinkCOOSell4,781$4.60$21,992.604,781View SEC Filing  
10/6/2016Edward WirthInsiderSell3,415$4.12$14,069.80View SEC Filing  
10/6/2016Katharine E. SpinkCOOSell4,781$4.11$19,649.91View SEC Filing  
9/9/2016Edward WirthInsiderSell14,760$3.52$51,955.20View SEC Filing  
9/9/2016Katharine E. SpinkCOOSell19,336$3.52$68,062.72View SEC Filing  
6/30/2016Stephen Lahue CarttCEOBuy10,000$2.40$24,000.00260,000View SEC Filing  
6/29/2016Richard T LebuhnDirectorBuy5,000$2.38$11,900.0025,000View SEC Filing  
6/10/2016Stephen Lahue CarttCEOBuy50,000$2.93$146,500.00250,000View SEC Filing  
6/9/2016Alfred D KingsleyDirectorBuy4,000$2.93$11,720.009,000View SEC Filing  
5/13/2016Natale S RicciardiDirectorBuy14,706$3.39$49,853.3419,706View SEC Filing  
9/16/2015Cary PinkowskiDirectorSell409,000$0.02$6,135.00
9/15/2015Edward WirthinsiderSell2,880$6.00$17,280.00View SEC Filing  
9/15/2015Katharine E. SpinkCOOSell3,760$6.00$22,560.00View SEC Filing  
9/14/2015Cary PinkowskiDirectorSell394,000$0.02$5,910.00
6/25/2015Andrew ArnoDirectorBuy5,000$4.32$21,600.00View SEC Filing  
2/9/2015Pedro LichtingerCEOBuy128,205$3.90$499,999.50View SEC Filing  
10/1/2014Scarsdale Equities LlcMajor ShareholderBuy60,000$5.93$355,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Asterias Biotherapeutics (NYSEAMERICAN AST) News Headlines

Source:
DateHeadline
Notable Friday Option Activity: AST, WIFI, PTCT - NasdaqNotable Friday Option Activity: AST, WIFI, PTCT - Nasdaq
www.nasdaq.com - February 17 at 3:37 PM
Asterias Expands Global IP Portfolio with New Patents, Including Key Additional Patent Protection for its Cancer ... - GlobeNewswire (press release)Asterias Expands Global IP Portfolio with New Patents, Including Key Additional Patent Protection for its Cancer ... - GlobeNewswire (press release)
globenewswire.com - February 17 at 3:37 PM
Asterias Expands Global IP Portfolio with New Patents, Including Key Additional Patent Protection for its Cancer Immunotherapy ProgramAsterias Expands Global IP Portfolio with New Patents, Including Key Additional Patent Protection for its Cancer Immunotherapy Program
finance.yahoo.com - February 15 at 3:38 PM
Asterias Biotherapeutics Inc (AST) Sees Significant Growth in Short InterestAsterias Biotherapeutics Inc (AST) Sees Significant Growth in Short Interest
www.americanbankingnews.com - February 9 at 8:06 PM
Short Interest in Asterias Biotherapeutics Inc (AST) Expands By 0.1%Short Interest in Asterias Biotherapeutics Inc (AST) Expands By 0.1%
www.americanbankingnews.com - January 30 at 2:44 PM
Asterias Biotherapeutics (AST) Stock Rating Lowered by Zacks Investment ResearchAsterias Biotherapeutics (AST) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 19 at 6:02 PM
Short Interest in Asterias Biotherapeutics Inc (AST) Declines By 2.6%Short Interest in Asterias Biotherapeutics Inc (AST) Declines By 2.6%
www.americanbankingnews.com - January 11 at 2:36 AM
Asterias Biotherapeutics (AST) "Buy" Rating Reaffirmed at HC WainwrightAsterias Biotherapeutics' (AST) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - January 8 at 7:26 AM
33 Stocks Moving In Thursdays Mid-Day Session | Benzinga - Benzinga33 Stocks Moving In Thursday's Mid-Day Session | Benzinga - Benzinga
www.benzinga.com - January 4 at 4:43 PM
Asterias Biotherapeutics reports milestone targets for 2018 - Seeking AlphaAsterias Biotherapeutics reports milestone targets for 2018 - Seeking Alpha
seekingalpha.com - January 4 at 4:43 PM
Asterias Biotherapeutics Reports Milestone Targets for 2018 - Nasdaq - NasdaqAsterias Biotherapeutics Reports Milestone Targets for 2018 - Nasdaq - Nasdaq
www.nasdaq.com - January 4 at 3:43 PM
Asterias Biotherapeutics Reports Milestone Targets for 2018Asterias Biotherapeutics Reports Milestone Targets for 2018
finance.yahoo.com - January 4 at 10:07 AM
ETFs with exposure to Asterias Biotherapeutics, Inc. : December 28, 2017ETFs with exposure to Asterias Biotherapeutics, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 4:25 PM
Asterias Biotherapeutics Inc (AST) Short Interest Up 6.3% in DecemberAsterias Biotherapeutics Inc (AST) Short Interest Up 6.3% in December
www.americanbankingnews.com - December 27 at 6:38 PM
Asterias Biotherapeutics, Inc. :AST-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017Asterias Biotherapeutics, Inc. :AST-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 12:57 PM
Wired News – Asterias Reports Enrollment and Dosing of Last Subject in SciStar Trial In Treatment of Severe Spinal Cord InjuryWired News – Asterias Reports Enrollment and Dosing of Last Subject in SciStar Trial In Treatment of Severe Spinal Cord Injury
finance.yahoo.com - December 21 at 10:12 AM
BioTime to Participate in The LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018 - Business Wire (press release)BioTime to Participate in The LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018 - Business Wire (press release)
www.businesswire.com - December 20 at 3:42 PM
BRIEF-Asterias Biotherapeutics Completes Enrollment Of Entire SCiStar StudyBRIEF-Asterias Biotherapeutics Completes Enrollment Of Entire SCiStar Study
www.reuters.com - December 19 at 4:40 PM
Asterias Biotherapeutics Completes Enrollment of Entire SCiStar Study - NasdaqAsterias Biotherapeutics Completes Enrollment of Entire SCiStar Study - Nasdaq
www.nasdaq.com - December 19 at 10:15 AM
Asterias Biotherapeutics Completes Enrollment of Entire SCiStar StudyAsterias Biotherapeutics Completes Enrollment of Entire SCiStar Study
finance.yahoo.com - December 19 at 10:15 AM
Asterias Biotherapeutics Inc (AST) Sees Large Decrease in Short InterestAsterias Biotherapeutics Inc (AST) Sees Large Decrease in Short Interest
www.americanbankingnews.com - December 12 at 2:26 AM
Asterias Biotherapeutics Inc (AST) Short Interest Up 4.9% in NovemberAsterias Biotherapeutics Inc (AST) Short Interest Up 4.9% in November
www.americanbankingnews.com - November 27 at 7:48 PM
Asterias Biotherapeutics Inc (AST) Stock Rating Lowered by Zacks Investment ResearchAsterias Biotherapeutics Inc (AST) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - November 22 at 5:10 PM
Asterias Biotherapeutics Inc (AST) Stock Rating Reaffirmed by HC WainwrightAsterias Biotherapeutics Inc (AST) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - November 22 at 8:05 AM
Asterias Biotherapeutics to Present at Piper Jaffray Healthcare Conference on November 28, 2017 - GlobeNewswire (press release)Asterias Biotherapeutics to Present at Piper Jaffray Healthcare Conference on November 28, 2017 - GlobeNewswire (press release)
globenewswire.com - November 16 at 9:25 PM
Asterias Biotherapeutics to Present at Piper Jaffray Healthcare Conference on November 28, 2017Asterias Biotherapeutics to Present at Piper Jaffray Healthcare Conference on November 28, 2017
finance.yahoo.com - November 16 at 4:24 PM
ETFs with exposure to Asterias Biotherapeutics, Inc. : November 15, 2017ETFs with exposure to Asterias Biotherapeutics, Inc. : November 15, 2017
finance.yahoo.com - November 16 at 11:33 AM
Asterias Biotherapeutics posts 3Q lossAsterias Biotherapeutics posts 3Q loss
finance.yahoo.com - November 16 at 11:33 AM
Astur Gold Corp (AST) Sees Significant Decline in Short InterestAstur Gold Corp (AST) Sees Significant Decline in Short Interest
www.americanbankingnews.com - November 14 at 12:02 AM
Astur Gold Corp (AST) Scheduled to Post Earnings on TuesdayAstur Gold Corp (AST) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - November 13 at 8:20 PM

SEC Filings

Asterias Biotherapeutics (NYSEAMERICAN:AST) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Asterias Biotherapeutics (NYSEAMERICAN AST) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.